The NORDIC NEC study evaluated 305 patients with G3-neuroendocrine cancer (NEC) and revealed that NEC patients with Ki67 < 55% were less responsive to chemotherapy than patients with Ki67 > 55% [43]. This evidence concerns the gene MKI67 and neuroendocrine carcinoma.